Vonicog alfa for Prophylaxis of Haemorrhage in Von Willebrand disease

Vonicog alfa is currently in clinical development for the prevention (prophylaxis) of bleeding episodes in patients with von Willebrand disease (VWD). VWD is a genetic bleeding disorder caused by a deficiency or absence of a blood clotting factor, called the von Willebrand factor. This causes poor blood clotting, which results in difficulty in stopping the flow of blood from a wound, causing prolonged bleeding. Current therapy includes preventative (prophylactic) treatment where medicine is used to prevent bleeding, or on-demand treatment, where medicine is used to treat prolonged bleeding.